| Today's Big NewsSep 28, 2022 |
| By Max Bayer Eisai and Biogen's recent phase 3 victory has once again placed the spotlight on amyloid beta. A slate of late-stage drugs, including lecanemab, are targeting amyloid plaque buildup to treat Alzheimer's. |
|
|
|
By Nick Paul Taylor,Gabrielle Masson Eisai’s phase 3 clinical trial of Biogen-partnered Alzheimer’s disease candidate lecanemab has hit its primary and key secondary endpoints. The result, which analysts called a “major surprise,” gives a big boost to the partners as they head toward an accelerated approval decision in January. |
Sponsored By THREAD One aspect of study design to consider when building better research experiences for patients is a genuinely patient-centered eCOA (electronic clinical outcome assessment) program. Here are some tips for ensuring that your eCOA is built with the needs of patients in mind and able to deliver the kind of engagement necessary for successful trials. |
Sponsored By Agilex Biolabs Australia’s largest and most technologically advanced provider of regulated bioanalysis and toxicology studies increases capacity by 500% with addition of new in-vivo facility in Brisbane |
By Gabrielle Masson Context Therapeutics is “cutting all excess fat” so it can stay afloat through 2024, putting nonessential activities on hold to “focus on blocking and tackling for the time being,” CEO Martin Lehr has told Fierce Biotech. |
By Max Bayer Pheon is nabbed $68 million in series A funds to launch its antibody-drug conjugate-focused pipeline. The company says the money will help fund a proof-of-concept study of its lead asset. |
By Nick Paul Taylor TCR2 Therapeutics has reported updated data from a phase 1 clinical trial of gavo-cel, linking the T-cell therapy to a 22% response rate in solid tumor patients who received the treatment after chemotherapy depletion. |
By Gabrielle Masson Nykode Therapeutics has taken aim at the holy grail of COVID-19 shots: a pan-variant vaccine that would eliminate the need for redesigning vaccines every time a new dominant variant comes around. |
By Andrea Park Philips’ respiratory device-focused Respironics business has been in the hot seat for well over a year now, ever since it identified a potentially fatal safety issue with the sound-muffling foam of around 5.5 million of its CPAP and BiPAP machines and other ventilators. |
By Fraiser Kansteiner A confluence of public health emergencies, armed conflict and historic pricing pressures are taking a toll on Europe’s supply of cheaper, off-patent medicines. In particular, soaring gas and electricity costs are threatening to upend certain manufacturers’ operations lest the EU intervene, the companies warned. |
By Joseph Keenan Emmes snapped up Clinical Edge for an undisclosed price, extending the Maryland-based CRO’s string of acquisitions to five in just under two years. |
By Nick Paul Taylor The U.K. drug regulator has told healthcare professionals to exercise caution when considering switching between long-acting attention-deficit/hyperactivity disorder therapies from companies including Johnson & Johnson, Novartis and Takeda. |
By Joseph Keenan BioIVT has bought Fidelis Research for an undisclosed price, marking the second acquisition for the biological specimens and services firm this month. |
Fierce podcasts Don't miss an episode |
| This week on "Podnosis," we talk about how AI is helping patients and what’s standing in the way of more widespread use. We also chat about how payers have invested in bringing on expertise necessary to tackle social determinants of health |
|
|---|
|
|
eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
Executive Summary How a new app brings the power of CRM to a leading lab instruments provider’s field service engineers Sponsored by: Cognizant |
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation Sponsored by: ReachBio | The Cell Biology Experts™ |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens. Sponsored by: DocuSign |
Research Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members Sponsored by: Genpact |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
Research TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases. Sponsored by: Unlearn AI |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
Multimedia ZS helps life sciences companies shape the future of medicine by turning healthcare data into transformative insights. Discover the power of R&D innovation Sponsored by: ZS |
| |
|
